Additional Relevant Details Incyte Corporation announced its decision to discontinue its Phase 3 trial (JANUS 1) of ruxolitinib in combination with capecitabine.  The decision is based off interim analysis that demonstrated "ruxolitinib plus capecitabine did not show a sufficient level of efficacy to warrant continuation".  Following these results, the Company has also decided to discontinue other Incyte-sponsored trials of ruxolitinib in solid tumors.  This includes Phase 3 JANUS 2 study in pancreatic cancer, the Phase 2 sub-study in patients with metastatic colorectal cancer and low CRP, the Phase 2 studies in breast and lung cancer and dose finding study of INCB39110 (a selective JAK1 inhibitor).